Start Submission Become a Reviewer

Reading: Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase G...

Download

A- A+
Alt. Display

Case Reports

Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia

Authors:

Félix Javier Jiménez-Jiménez ,

Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, ES
About Félix Javier
felix.jimenez@sen.es
X close

José A. G. Agúndez,

Department of Pharmacology, University of Extremadura, Cáceres, ES
X close

Carmen Martínez,

Department of Pharmacology, University of Extremadura, Cáceres, ES
X close

Francisco Navacerrada,

Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, ES
X close

José Francisco Plaza-Nieto,

Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, ES
X close

Belén Pilo-de-la-Fuente,

Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, ES
X close

Hortensia Alonso-Navarro,

Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, ES
X close

Elena García-Martín

Department of Biochemistry and Molecular Biology, University of Extremadura, Cáceres, ES
X close

Abstract

Background: Hereditary coproporphyria (HCPO) is a low-penetrance, autosomal dominant, acute hepatic porphyria characterized by the overproduction and excretion of coproporphyrin. The most common neurological manifestations of this entity include peripheral, predominantly motor dysfunction, and central nervous system dysfunction. Ataxia associated with HCPO has not been reported previously. The aim of this article is to report a patient with HCPO presenting with acute ataxia.

Case Report: We describe a 44-year-old patient presenting clinically with acute ataxia who was diagnosed with HCPO; mutations were analyzed in the coproporphyrin-oxidase III (CPOX) gene in the patient and in six asymptomatic first-degree relatives.

Discussion: The patient was heterozygous for a mutation causing the amino acid exchange Q306X in the CPOX gene. No relatives carried the same or another mutation in the CPOX gene. HCPO should be considered in the differential diagnosis for patients presenting with ataxia.

How to Cite: Jiménez-Jiménez FJ, Agúndez JAG, Martínez C, Navacerrada F, Plaza-Nieto JF, Pilo-de-la-Fuente B, et al.. Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia. Tremor and Other Hyperkinetic Movements. 2013;3:tre-03-151-4162-1. DOI: http://doi.org/10.5334/tohm.145
  Published on 25 Jul 2013
 Accepted on 26 Feb 2013            Submitted on 28 Dec 2012

Introduction

Porphyrias are metabolic diseases that develop from either inherited or, more infrequently, acquired disturbances of heme biosynthesis, leading to an overproduction of heme precursors in liver and bone marrow. Porphyrias are divided into acute hepatic, chronic hepatic, and erythropoietic types depending on the main site of expression of the enzymatic defect. Eight enzymes are involved in the eight steps of heme biosynthesis, and deficiencies in seven of them (except the delta-aminolevulinic synthase, responsible for the first step) each correlate with a specific form of porphyria.1,2

Patients suffering from acute porphyrias share a common clinical symptom of acute, severe abdominal pain attacks. In addition, symptoms such as nausea, vomiting, hypertension, tachycardia, and hyponatremia are present in most porphyric crises. Severe or prolonged attacks are accompanied by peripheral, predominantly motor dysfunction, and central nervous system dysfunction.3 The presence of light-induced skin symptoms due to the dermal accumulation of the photosensitizing porphyrins, mainly blisters, ulcers, and skin fragility, are common in some acute porphyrias.3

Hereditary coproporphyria is a low-penetrance, autosomal dominant, acute hepatic porphyria characterized by the overproduction and excretion of coproporphyrin. The disease is the result of deficient activity of the mitochondrial enzyme coproporphyrinogen oxidase (CPOX, EC1.3.3.3) as a consequence of the inheritance of mutations in the CPOX gene (chromosome 3q12; OMIM 612732, gene ID 1371). In most cases, enzyme activity is reduced to nearly 50% in heterozygotes. Clinical crises are characterized by an acute polysymptomatic syndrome with abdominal, cardiovascular, neurological, and psychiatric symptoms; nearly 20% of patients may experience photosensitivity.1,3,4 At least 36 different mutations in the CPOX gene, with a high proportion of missense mutations, have been described.57 We report a patient who was diagnosed with hereditary coproporphyria associated with a mutation in the CPOX gene presenting with acute ataxia.

Case report

The propositus was a 44-year-old male. He was a heavy smoker (60 cigarettes per day) and a moderate ethanol consumer, but had no other medical antecedents of interest. He did not consume drugs or herbal. He was admitted to the hospital for sudden onset of dizziness, severe gait unsteadiness, and difficulty with speech. The previous day he had been painting a metallic staircase with red lead paint. General examination revealed no abnormalities. Neurological examination showed scanning speech (considerably slow and dysarthric speech with pronounced slurring, most words being understandable), a mild vertical skew deviation of eyes without nystagmus, severe gait and trunk ataxia (the patient could only walk assisted by another person, gait speed was extremely low, he was unable to stand with feet together but was able to stand in a natural position with considerable sway and corrections, and he had moderate oscillations of the trunk and legs while sitting), mild dysmetria, and mild action tremor in the finger-to-nose and the finger-to-finger tests; moderate dysmetria and mild action tremor in the heel-to-knee test, and moderate dysdiadochokinesia for pronation supination alternating movements. The basal scores of the International Cooperative Ataxia Rating Scale (ICARS)8 are given in Table 1.

Table 1

Scores of the International Cooperative Ataxia Rating Scale (ICARS) before Treatment with Heme Arginate and 2 Weeks After Treatment

ICARS Subscale ICARS Item Pre-treatmentScore (Day 0) Post-treatmentScore (Day 15)
Posture and gait disturbances Walking capacities 7/8 5/8
Gait speed 3/4 2/4
Standing capacities, eyes open 4/6 3/6
Spread of feet in natural position without support, eyes open 3/4 2/4
Body sway with feet together, eyes open 3/4 2/4
Body sway with feet together, eyes closed 3/4 2/4
Quality of sitting position 2/4 1/4
Posture and gait score (static score) 25/34 17/34
Kinetic function Knee-tibia test 6/8 2/8
Action tremor in the heel-to-knee test 2/8 2/8
Finger-to-nose test: decomposition and dysmetria 4/8 2/8
Finger-to-nose test: intention tremor of the finger 2/8 2/8
Finger–finger test: action tremor and/or instability 4/8 2/8
Pronation supination altering movements 4/8 2/8
Drawing of the Archimedes spiral on a pre-drawn pattern 2/4 2/4
Kinetic score (limb coordination) 24/52 14/52
Speech disorders Dysarthria: fluency of speech 3/4 1/4
Dysarthria: clarity of speech 2/4 1/4
Dysarthria score 5/8 2/8
Oculomotor disorders Gaze-evoked nystagmus 0/3 0/3
Abnormalities of the ocular pursuit 1/2 1/2
Dysmetria of the saccade 1/1 1/1
Oculomotor movement score 2/6 2/6
Total ataxia score 56/100 35/100

Blood count, routine biochemistry; copper and iron metabolism studies; and serum levels of thyroid hormones, vitamins A, B1, B6, B12, E, folic acid, proteinogram, immunoglobulins, C3, and C4 were normal. Serological studies for syphilis; Brucella; Borrelia; hepatitis A, B, and C; HIV, herpesvirus simplex 1 and 2, herpesvirus zoster; cytomegalovirus; Epstein–Barr virus; and measles were negative. Antinuclear antibodies, anti-Sjögren syndrome A and B, antineutrophil cytoplasmic, antigliadin antibodies, and cryoglobulins were negative. Tumor markers, including carcinogenic embryogenic antigen; alpha-fetoprotein; carbohydrate antigen (CA)125, CA19-9, and CA15-3; neuron-specific enolase; and prostatic-specific antigen were negative. Anti-Yo and anti-Hu antigens were negative both in serum and in cerebrospinal fluid (CSF). A test for 14-3-3 protein in CSF was also negative.

Brain computed tomography (CT) scan, brain magnetic resonance imaging, and thoraco-abdomino-pelvic CT scan were normal. Routine CSF analysis showed no abnormalities. Electromyography and nerve conduction studies were normal. Molecular genetic studies for Friedreich’s ataxia; spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, 12, and 17; and dentate-rubro-pallido-luysian atrophy were negative. Serum levels and 24-hour urinary excretion of lead were normal. The measurement of urinary excretion of porphyrins and their precursors showed a marked increase in excretion of coproporphyrins (1478 µg/24 hours; normal values 0.0–160.0 µg/24 hours) and total porphyrins (1616 µg/24 hours, normal values 0.0–200.0 µg/ 24 hours), a moderate increase in uroporphyrin excretion (138 µg/24 hours, normal values 0.0–60.0 µg/24 hours), a mild increase in excretion of porphobilinogen (2.53 mg/24 hours, normal values 0.0–2.0 mg/24 hours), and decreased concentration of delta-aminolevulinic acid (0.12 mg/g of creatinine; normal values 1.0–7.0 mg/g of creatinine).

The patient was treated with intravenous heme arginate (Normosang, 250 mg per day) for 10 days. This treatment led to a moderate clinical improvement of ataxia as assessed with ICARS8 (pre- and post-treatment scores, 15 days after the onset of the treatment, are given in Table 1) and normalized values of urinary excretion of coproporphyrins (155 µg/24 hours), uroporphyrins (30 µg/24 hours), and total porphyrins (195 µg/24 hours). Two months later, the patient developed a severe behavioral disorder with aggressiveness, which resulted in divorce, and follow-up was lost.

We investigated the presence of mutations in all CPOX gene exons in the propositus: his mother aged 76 years (the father was deceased); one of his two brothers, aged 47 years; and his four sons, aged 11, 9, 7, and 5 years. All the relatives of the propositus were asymptomatic and provided written informed consent to this analysis (in the case of the children, written informed consent was provided by their mother).

DNA was isolated from peripheral lymphocytes. Sequencing analysis was performed as follows: first, fragments comprising the whole exon and the 5′- and 3′- flanking regions were amplified using the primers described in Table 2, then amplified fragments were analyzed by direct sequencing as described elsewhere.9 Sequencing analyses were repeated in triplicate. Details for amplification conditions and oligonucleotides utilized for sequencing analyses are available on request.

Table 2

Primers Used to Amplify the Seven Exons of the CPOX Gene

Fragment Forward Reverse
Exon 1 AGCTCGCCGGCTCAATACTC TGTGGGTACCCCCTACCTAC
Exon 2 GATTTGGGAAACGGGAAAAT GGGCAAAATAAGGTTTGCAG
Exon 3 GCCGCACGTTGACAAATACT TTGCCTTTACATTGCCTCCT
Exon 4 TTCTGCCTAGGCCTTACTGG TGTAATTTTGGGGTCATGAAA
Exon 5 ACCTGAAAGGCTCAC TAAGAGCTGCTCCAC
Exon 6 GCTGTAGGCTGGTGTCCTCT TTGGGAATTGGGAGTGTAGG
Exon 7 TGTGGCACAAATGAAAACTTTA TGCTTTTGTTTTGGACATGC

The propositus was heterozygous for the mutation causing the amino acid exchange Q306X (exon 4) described elsewhere.7 None of the patient’s relatives had CPOX gene mutations.

Discussion

Our patient presented with acute ataxia following exposure to industrial red lead paint. Etiological studies on possible causes of hereditary or acquired ataxias were negative. However, because urine analysis showed a marked excretion of coproporphyrins and of total porphyrins, the patient was diagnosed with hereditary coproporphyria. This clinical entity is considered a very rare disease in Spain, where to our knowledge only six cases have been reported to date.6,10,11 The rationale of testing this patient for porphyria was the exposure of the patient to red lead paint, which could act as a trigger of acute porphyria.12,13

Although we cannot rule out the association of ataxia and biochemical features of hereditary coproporphyria in our patient as coincidental, the clinical improvement of ataxia after treatment with heme arginate (together with improvement in biochemical parameters) seems to support this association. Prior to the development of ataxia, our patient had never suffered from recurrent abdominal pain or experience any skin or cardiovascular symptoms or symptoms suggesting peripheral or central nervous system dysfunction.

The mutations analysis performed on the patient and his asymptomatic first-degree relatives revealed that he was the only member of the family who had a previously reported mutation in the CPOX gene (Q306X).7 To our knowledge, the presentation of hereditary coproporphyria with acute ataxia has not been reported. The possibility that this symptom could be related to the presence of the Q306X mutation is unclear. Urinary analysis of porphyrins could be useful in the study of patients with acute ataxia.

Notes

1 Funding: Grants PS09/00943, PS09/00469, PI12/00241, PI12/00324, RETICS RIRAAF RD12/0013/0002, and Grant GR10068 from Junta de Extremadura, Spain and from Neuro-Magister S.L. Financed in part with FEDER funds from the European Union. 

2 Financial disclosures: None. 

3 Conflict of Interests: The authors report no conflicts of interest. 

Acknowledgements

We thank Gara Esguevillas for her technical assistance and Professor James McCue for his assistance in language editing.

References

  1. Gross, U, Hoffmann, GF and Doss, MO (2000). Erytrhopoietic and hepatic porphyrias. J Inherit Metab Dis 23: 641–661, DOI: https://doi.org/10.1023/A:1005645624262 [PubMed]  

  2. Sassa, S (2006). Modern diagnosis and management of the porphyrias. Br J Haematol 135: 281–292, DOI: https://doi.org/10.1111/j.1365-2141.2006.06289.x [PubMed]  

  3. Schneider-Yin, X, Harms, J and Minder, EI (2009). Porphyria in Switzerland, 15 years experience. Swiss Med Wkly 139: 198–206. [PubMed]  

  4. Kühnel, A, Gross, U and Doss, MO (2000). Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem 33: 465–473, DOI: https://doi.org/10.1016/S0009-9120(00)00159-4 [PubMed]  

  5. Rosipal, R Lamoril, J Puy, H et al. (1999). Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. Hum Mutat 13: 44–53, DOI: https://doi.org/10.1002/(SICI)1098-1004(1999)13:1<44::AID-HUMU5>3.0.CO;2-Q [PubMed]  

  6. To-Figueras, J Bádenas, C Enríquez, MT et al. (2005). Biochemical and genetic characterization of four cases of hereditary coproporphyria in Spain. Mol Genet Metab 85: 160–163, DOI: https://doi.org/10.1016/j.ymgme.2004.12.012 [PubMed]  

  7. Lee, DS, Flachsová, E, Bodnárová, M, Demeler, B, Martásek, P and Raman, CS (2005). Structural basis of hereditary coproporphyria. Proc Natl Acad Sci USA 102: 14232–14237, DOI: https://doi.org/10.1073/pnas.0506557102 [PubMed]  

  8. Trouillas, P Takayanagi, T Hallett, M et al. (1997). International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145: 205–211, DOI: https://doi.org/10.1016/S0022-510X(96)00231-6 [PubMed]  

  9. Garcia-Martin, E Martinez, C Pizarro, RM et al. (2002). CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 71: 196–204, DOI: https://doi.org/10.1067/mcp.2002.121371 [PubMed]  

  10. Morell, F Frisón, JC Richart, C et al. (1975). Coproporfiria hereditaria: aportación de un caso. Rev Clin Esp 139: 357–361. [PubMed]  

  11. Taxonera, C, Enríquez de Salamanca, R, Chinarro, S, Enríquez de Salamanca, C, Ruiz de León, A and Díaz-Rubio, M (1985). Coproporfiria hereditaria: primeros casos descritos en España. An Med Interna 2: 278–280.  

  12. Mamet, R, Sztern, M, Rachmel, A, Stahl, B, Flusser, D and Schoenfeld, N (2001). Lead poisoning: a new biochemical perspective on the differentiation between acquired and hereditary neuroporphyria. Clin Chem 47: 1710–1713. [PubMed]  

  13. Fujita, H, Nishitani, C and Ogawa, K (2002). Lead, chemical porphyria, and heme as a biological mediator. Tohoku J Exp Med 196: 53–64, DOI: https://doi.org/10.1620/tjem.196.53 [PubMed]  

comments powered by Disqus